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Abstract
Background
Recent in vitro and animal experiments suggest that peroxisome proliferation-activated
receptor gamma (PPARɣ) agonist medications, such as antidiabetic glitazone (GTZ) drugs,
are neuroprotective in models of Parkinson’s disease (PD). These findings have not been
tested in humans. We hypothesized that individuals prescribed GTZ drugs would have a
lower incidence of PD compared to individuals prescribed other treatments for diabetes.
Methods and Findings
Using primary care data from the United Kingdom Clinical Practice Research Datalink
(CPRD), we conducted a retrospective cohort study in which individuals with diabetes who
were newly prescribed GTZ (GTZ-exposed group) were matched by age, sex, practice,
and diabetes treatment stage with up to five individuals prescribed other diabetes treat-
ments (other antidiabetic drug-exposed group). Patients were followed up from 1999 until
the first recording of a PD diagnosis, end of observation in the database, or end of the study
(1 August 2013). An incidence rate ratio (IRR) was calculated using conditional Poisson
regression, adjusted for possible confounders. 44,597 GTZ exposed individuals were
matched to 120,373 other antidiabetic users. 175 GTZ-exposed individuals were diagnosed
with PD compared to 517 individuals in the other antidiabetic drug-exposed group. The inci-
dence rate (IR) of PD in the GTZ-exposed group was 6.4 per 10,000 patient years com-
pared with 8.8 per 10,000 patient years in those prescribed other antidiabetic treatments
(IRR 0.72, 95% confidence interval [CI] 0.60–0.87). Adjustments for potential confounding
variables, including smoking, other medications, head injury, and disease severity, had no
material impact (fully adjusted IRR 0.75, 0.59–0.94). The risk was reduced in those with cur-
rent GTZ prescriptions (current GTZ-exposed IRR 0.59, 0.46–0.77) but not reduced among
those with past prescriptions (past GTZ-exposed IRR 0.85, 0.65–1.10). Our study only
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included patients with diabetes who did not have a PD diagnosis when they were first pre-
scribed GTZ, and thus, it cannot establish whether GTZ use prevents or slows the progres-
sion of PD.
Conclusions
In patients with diabetes, a current prescription for GTZ is associated with a reduction in
incidence of PD. This suggests PPAR gamma pathways may be a fruitful drug target in PD.
Introduction
Parkinson’s disease (PD) is a common, progressive degenerative neurological disease, with a
markedly increased prevalence with older age [1]. It is principally characterised by neurode-
generation of the nigrostriatal neurons and a consequent deficit in striatal dopamine content
[2,3]. Until now, no effective treatments have been found to tackle directly the neurodegenera-
tive aspect of PD.
Promising in vitro and in vivo studies with rodents show that peroxisome proliferation-acti-
vated receptor gamma (PPARɣ) agonist medications, such as the antidiabetes glitazone (GTZ)
drugs pioglitazone and rosiglitazone, may have neuroprotective effects by inhibiting microglial
activation [4–6]. There is one ongoing small clinical trial among patients with PD looking at
disease progression (Clinicaltrials.gov registration: NCT01280123), but there are no published
human data on whether GTZ drugs are protective against PD.
Utilizing electronic health records, we aimed to determine whether there is a protective
association between exposure to GTZ antidiabetic medications and PD in a large primary care
population of people with diabetes.
Methods
Our study protocol was approved by the Independent Scientific Advisory Committee for
MHRA database research (Independent Scientific Advisory Committee [ISAC] protocol num-
ber 13_016, February 2013). Studies using anonymised CPRD data for ISAC-approved obser-
vational research are covered by CPRD’s broad MREC ethics approval, without the need for
specific informed consent.
Data Source and Study Design
A cohort study was conducted among people with type 1 and 2 diabetes within the United
Kingdom Clinical Practice Research Datalink (CPRD), a well-established research database of
electronic health records. CPRD collects and archives the anonymised medical, laboratory,
referral, and prescribing records of primary care practices. CPRD data are demographically
and geographically representative of the UK population, representing around 8% of it [7,8].
This study used the medical records of patients registered at one of 680 participating practices,
comprising 13,291,839 active patients in October 2013 (month of data retrieval). As primary
care is free at the point of delivery, it has almost universal coverage in the UK. The database
has been described in detail elsewhere [9].
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Selection of GTZ Users and the Comparison Group
The study population was drawn from the entire CPRD population, with follow-up time from
the first of January 1999 onwards, when rosiglitazone was introduced. This was a dynamic
cohort, with follow up ending at the earliest of the following: the date the patient left the prac-
tice, death date, or the latest date of data collection (1August 2013). Exposed patients were
selected for inclusion if they had received any prescription for a GTZ (code list in S1 Text),
with the first occurrence being at least 12 months after the patient’s start of follow up to ensure
incident use. No age restrictions were applied. Each GTZ-exposed patient was matched by age
(within 5 years), sex, practice, and treatment stage (see “Definition of Exposure and Treatment
Stages”) with one to five patients starting other treatments for diabetes from 1999 onwards,
again with at least 12 months prior registration in the database (other antidiabetic drug-
exposed group). Individuals in the control pool who were eligible as potential matches for both
first-line GTZ users and second-line GTZ users were removed from the potential control pool
once selected as a match for first-line GTZ users. Follow up for all patients began at the first
prescribing event that made them eligible for inclusion (index date). Patients in the GTZ-using
group exposed to other antidiabetic drugs prior to the start of their GTZ follow up were eligible
as potential matches pre-GTZ use. Potential participants with any diagnosis of PD prior to
their index date were excluded. The time index used in this study was follow-up time in years
after study entry. The mean follow-up time was 5.23 years (standard deviation 3.75), with a
range of 0 to 14.57 years.
Definition of Exposure and Treatment Stages
Exposure was defined as a recorded prescription for an antidiabetic agent listed in chapter 6.1
of the British National Formulary (BNF). To account for missing information regarding dose
and duration of treatment, the median obtained from all other prescriptions of the same drug
was imputed if no other information was available. In the primary analysis, exposure was char-
acterized as “ever exposed” versus “never exposed” to GTZ drugs in a time-updated manner:
GTZ-exposed individuals at the start of their follow-up time remained ever exposed regardless
of any subsequent changes in therapy; nonusers starting a GTZ during follow up changed from
never exposed to ever exposed from the date of the change.
GTZ-exposed and other antidiabetic drug-exposed individuals were classified according to
their diabetes treatment stage at the index date as shown in Fig 1: stage (1) monotherapy with
GTZ only or monotherapy with any other antidiabetic drugs, with no prior pharmaceutical
treatment for diabetes received; stage (2) second-line GTZ as monotherapy or a second-line
other antidiabetic drug as monotherapy, with the first-line antidiabetic drug discontinued; and
stage (3) second-line GTZ in combination with one or more other antidiabetic drugs, versus
any other non-GTZ antidiabetic drugs in combination of two or more drugs (see Fig 1).
Identification of Patients with PD
The outcome for this study was the first recording of a PD diagnosis after the index date. Peo-
ple with a first recorded occurrence of PD were identified using clinical and referral records,
using the Read code list in S2 Text. Any person with a diagnosis of PD due to known causes
(such as drug-induced PD), based on the recording of codes presented in S2 Text, was censored
at the date of the diagnosis.
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Statistical Methods
Wemeasured an incidence rate ratio (IRR) for the association between GTZ exposure and inci-
dent PD using conditional Poisson regression, conditional on the matched sets to control for
gender, age, practice, and treatment stage. GTZ-exposed individuals were compared with
patients exposed to alternative treatments. The primary analysis followed all patients from
their index date until the earliest of the following: recording of PD, transfer out/death, or last
data collection date for the practice.
Adjustments for potential confounding were made in a forward stepwise manner, retaining
variables in the model if they had a substantial impact on the estimated rate ratio for GTZ-
exposure (a change of 10% or more) and starting with variables associated with PD incidence
in univariate analyses. Additionally, we included a model adjusting for all potential confound-
ers. Covariates that were explored at the time of entry to the study because of their potential
Fig 1. Graphical representation of the three different treatment stages: Users of GTZ drugs and other antidiabetic drugs classified according to
first- or second-line mono- or combination therapy at the index date. For instance, to be a glitazone user in category (2), first-line non-GTZ treatment for
diabetes was discontinued after 1999 when a GTZ was prescribed as second-line monotherapy. A patient could be matched to a GTZ user in category (2) if
they had received an antidiabetic drug other than a GTZ (for example: Metformin) but stopped using their first-line antidiabetic treatment after 1999 and
began taking another drug (for example: Sulfonylurea) as monotherapy after at least 12 months of registered follow-up.
doi:10.1371/journal.pmed.1001854.g001
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association with both GTZ exposure and PD were current smoking, prescriptions for hormone
replacement therapy and calcium channel blockers, head trauma, calendar year, alcohol con-
sumption, and body mass index (BMI) [10–16]. A protective effect of diabetes, compared to
people without diabetes, has recently been reported [17]. Our analysis was restricted to people
with diabetes, but the degree of protection may be related to disease severity. As such, we
included measures of severity as confounders, including HbA1c level at the index date and dia-
betes duration to index date. In a secondary analysis, we also adjusted for time-updated age
(5-year age bands, except for 50–70 years for which we used 2-year bands) and calendar year
(see below).
All data management and analyses were performed using Stata 12 (StataCorp, Texas).
Secondary Analyses
Firstly, we took into account cessation of GTZ therapy by dividing GTZ-exposed follow-up
time into current and past use: users were designated as past users 180 days after their last GTZ
prescription. The 180 days represent a gradual shift from full exposure to an entirely unex-
posed state, allowing for potential delayed use of medication. Within this post hoc time-
updated analysis, a stratified analysis on length of follow up of current GTZ exposure was con-
ducted to assess whether the treatment association varied with exposure length. Secondly, a
stratified analysis was conducted to look separately at the association with pioglitazone and
rosiglitazone.
Sensitivity Analyses
We performed several sensitivity analyses:
1. Metformin has been suggested to also have a protective effect against PD [18]. To explore
any potential effect modification by metformin use, we performed an analysis restricted to
current or past metformin users.
2. A sensitivity analysis was conducted using a stricter definition of PD in which at least two
prescriptions for an anti-PD drug were required in addition to a Read code indicating PD,
to reduce the likelihood of outcome misclassification. The date of earliest recorded diagnosis
remained the date of the outcome.
3. Post hoc sensitivity analyses were conducted restricted to all users of antidiabetic agents
aged 40 and older; in a separate analysis, analyses were restricted to nonsmokers. Lastly, to
examine the association with oral antidiabetic agents only, we excluded individuals who
were prescribed insulin before or on the index date.
Results
Patient Characteristics
Of the 60,224 patients with a recorded GTZ prescription from 1999 onwards, 44,597 met the
inclusion criteria (see Fig 2). 13,988 GTZ-exposed individuals had less than 12 months of fol-
low-up time or were exposed to GTZ drugs before the start of follow up. 1,494 GTZ-exposed
individuals could not be matched to users of other antidiabetic drugs because of a lack of avail-
able matches with the same age, gender, treatment stage, and practice and were dropped from
the analyses, as were 145 GTZ users diagnosed with PD before GTZ use. For the primary analy-
sis, the GTZ-exposed individuals were matched to 120,373 other antidiabetic drug-exposed
individuals. The average follow-up time of GTZ-exposed individuals and those prescribed
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other antidiabetic treatments from the case index date within the matched set until the overall
end of follow up in CPRD was similar (6.1 versus 5.9 years). 81% of all patients in the GTZ-
exposed groups (n = 36,341) and 79% (n = 95,331) of those prescribed other treatments for dia-
betes were followed up from the start date until the final data collection date. Four percent of
all study participants (1,561 individuals exposed to GTZ drugs and 4,946 individuals exposed
to other treatments for diabetes) were followed up until they transferred to another primary
care practice, and the remaining patients (6,695 GTZ-exposed and 20,096 individuals exposed
to other treatments for diabetes) were followed up until their recorded death date. Most of the
GTZ-exposed group (94%) were prescribed second-line GTZ as dual therapy in combination
with metformin (55%) or sulphonylureas (39%). The characteristics of the GTZ-exposed and
the matched other antidiabetic drug-exposed group are presented in Table 1.
GTZ-exposed individuals were more likely than those prescribed other antidiabetic drugs to
have BMI> 25 kg/m2 and to have higher HbA1c levels at baseline. The average age of PD diag-
nosis in GTZ users was similar to non-GTZ users (73.2 versus 73.5 years). See S1 Table for a
comparison of individuals with and without PD.
Fig 2. Flow chart study population: Creation of the main dataset and reasons for exclusions
doi:10.1371/journal.pmed.1001854.g002
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Table 1. Patient demographics and characteristics: GTZ-exposed individuals versus other antidiabetic drug-exposed individuals.
Demographics, Characteristics GTZ-exposed individuals (n = 44,597) Other antidiabetic drug-exposed individuals (n = 120,373)
Median age (interquartile ranges) 62.7 (53.9–71.1) 63.6 (54.4–71.9)
Age range (years) 7.3–98.9 8.1–100.3
Sex, n (%)
Female 19,249 (43.2) 52,471 (43.6)
Male 25,348 (56.8) 67,902 (56.4)
Calendar year at index date, n (%)
1999–2003 10,019 (22.5) 43,982 (36.5)
2004–2008 26,090 (58.5) 37,463 (31.1)
2009–2013 8,488 (19.0) 38,928 (32.4)
Alcohol use at study entry, n (%)
No 6,487 (14.6) 21,302 (17.7)
Yes 30,633 (68.7) 77,281 (64.2)
Former 3,431 (7.7) 7,511 (6.2)
Excessive 2,378 (5.3) 7,135 (5.9)
Unknown 1,668 (3.7) 7,144 (5.9)
Smoking at study entry, n (%)
Current 7,403 (16.6) 22,411 (18.6)
Former smoker 22,483 (50.4) 56,041 (46.6)
Never 14,083 (31.6) 40,085 (33.3)
Unknown 628 (1.4) 1,836 (4.5)
BMI (kg/m2) at study entry, n (%)
<18.5 130 (0.3) 577 (0.5)
18.5–24.9 5,352 (12.0) 18,422 (15.3)
25.0–29.9 14,578 (32.7) 40,933 (34.0)
30 23,727 (53.2) 56,188 (46.7)
Unknown 810 (1.8) 4,253 (3.5)
Treatment stage, n (%)
First-line monotherapy 942 (2.1) 4,317 (3.6)
Second-line monotherapy 1,768 (4.0) 3,182 (2.6)
Second-line combination 41,887 (93.9) 112,874 (93.7)
Comorbidities, n (%)
Head injury 1,457 (3.3) 3,885 (3.2)
Diabetes duration
0–2 years before entry study 8,979 (20.1) 32,146 (26.7)
2–5 years before entry study 12,631 (28.3) 28,584 (23.7)
5–9 years before entry study 12,308 (27.6) 28,827 (23.9)
>9 years before entry study 10,595 (23.8) 30,438 (25.3)
Diabetes diagnosis missing 84 (0.2) 378 (0.3)
HbA1c levels
<7.5% (<57 mmol/mol) 8,419 (18.9) 37,912 (31.5)
7.6%–8.3% (>57 mmol/mol and <66 mmol/mol) 11,810 (26.5) 26,505 (22.0)
8.4%–9.6% (>66 mmol/mol and <80 mmol/mol) 12,444 (27.9) 25,005 (20.8)
>9.6% 11,751 (26.3) 28,966 (24.1)
HbA1c missing 173 (0.4) 1,985 (1.6)
Comedications, n (%)
Calcium channel blockers (CCB)
Never 28,115 (63.0) 78,397 (65.1)
(Continued)
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Results Primary Analysis
The incidence rate (IR) of PD in the GTZ-using group (6.4 per 10,000 patient years, 95% confi-
dence interval [CI] 5.5–7.4) was lower than the IR of PD in the matched comparison cohort
(8.8 per 10,000 patient years, 95% CI 8.1–9.6). The IRR, accounting for age, gender, practice,
and treatment stage by matching, showed strong evidence of a protective association between
use of GTZ drugs and the onset of PD (IRR 0.72, 95% CI 0.60–0.87, p-value< 0.001). The
results of the primary analysis are presented in Table 2. A similar association was found when
adjusting for all potential confounders (fully adjusted IRR 0.75, 0.59–0.94, p-value = 0.011; see
Table 3).
A simple test for interaction by age (above and below the median age) as a post hoc analysis
showed no evidence for effect modification by age (p-value = 0.9729).
Results Secondary Analyses
When the follow-up time of the GTZ–exposed group was updated to differentiate between the
current and past GTZ-exposed groups, a strong protective association was found for current
GTZ-exposure (IRR 0.59, 95% CI 0.46–0.77, p-value< 0.0001), but we observed a weaker, non-
significant association with past use (IRR 0.85, 95% CI 0.65–1.10, p-value = 0.209). A stratified
analysis on length of follow up of current GTZ exposure suggested no important variation in
rates of PD depending on duration of use (see Table 2).
The point estimate for the estimated protective association was stronger for rosiglitazone
compared to other antidiabetic drugs (IRR = 0.65, 0.52–0.82, p-value< 0.0001) than pioglita-
zone compared to other antidiabetic drugs (IRR = 0.89, 0.65–1.24, p-value = 0.496), but num-
bers of events were limited in the latter group, CIs overlapped, and a formal test suggested no
evidence of an interaction (p-value for interaction = 0.42).
Results Sensitivity Analyses
Restricting the cohort or changing the definition of PD did not have a material impact on the
main results: the association between exposure to GTZ drugs and the lower incidence of PD
remained (see Table 2).
Discussion
In a large population-based cohort study, we have shown for the first time that in individuals
with diabetes, a prescription for GTZ is associated with a 28% lower rate of clinical presenta-
tion of PD compared to those prescribed other antidiabetic agents. The estimated association
was similar when established risk factors, such as age and smoking, and possible risk factors,
Table 1. (Continued)
Demographics, Characteristics GTZ-exposed individuals (n = 44,597) Other antidiabetic drug-exposed individuals (n = 120,373)
Past user: Used >6 months before index date 6,811 (15.3) 23,287 (19.4)
Current user for <1 year 1,182 (2.7) 3,376 (2.8)
Current user for >1 year 8,489 (19.0) 15,313 (12.7)
Hormone replacement therapy (HRT)
Never 39,516 (88.6) 109,578 (91.0)
Past user: Used >6 months before index date 4,200 (9.4) 8,834 (7.3)
Current user for <1 year 67 (0.2) 324 (0.3)
Current user for >1 year 814 (1.8) 1,637 (1.4)
doi:10.1371/journal.pmed.1001854.t001
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such as head injury and BMI, were adjusted for. Results allowing for changes in GTZ exposure
showed strong evidence of a protective association between current GTZ exposure and PD
compared with other antidiabetic drug exposure (IRR 0.59, 95% CI 0.46–0.77). No significant
association was found for past exposure (IRR 0.85, 95% 0.65–1.10). Our results suggest that the
protective association is limited to periods of GTZ treatment, with little or no longer-lasting
benefit. This is supported by animal study data in which withdrawal of PPARγ therapy negates
any neuroprotective effect [19].
To our knowledge, this is the first population-based investigation of the relationship
between treatment with GTZ drugs and the incidence of PD. A clinical trial is currently
Table 2. IRR of PD: GTZ-exposed group versus the other antidiabetic drug-exposed group.
Type of Analysis Group Person
Years
PD
Cases
Adjusted IRR* (95%
CI)
Primary analysis: Other antidiabetic drug-exposed
group
587,767 517 1
GTZ-exposed group 273,435 175 0.72 (0.60–0.87)
Secondary analyses:
Time-updated follow-up periods:
Current GTZ-exposed group 156,532 89 0.59 (0.46–0.77)
Current 0–2 years** GTZ-exposed group 16,910 8 0.53 (0.25–1.12)
Current 2–3 years GTZ-exposed group 13,945 9 0.56 (0.27–1.17)
Current >3 years GTZ-exposed group 125,678 72 0.61 (0.46–0.81)
Past GTZ-exposed group 116,895 86 0.85 (0.65–1.10)
Analysis stratiﬁed by type of GTZ:
Pioglitazone Other antidiabetic drug-exposed
group
250,996 180 1
GTZ-exposed group 94,218 57 0.89 (0.65–1.24)
Rosiglitazone Other antidiabetic drug-exposed
group
336,771 337 1
GTZ-exposed group 179,207 118 0.65 (0.52–0.82)
Sensitivity analyses:
Analysis with secondary outcome deﬁnition Other antidiabetic drug-exposed
group
587,340 398 1
GTZ-exposed group 273,508 148 0.82 (0.66–1.00)
Analysis stratiﬁed by metformin use: Metformin Other antidiabetic drug-exposed
group
434,566 397 1
GTZ-exposed group 253,325 158 0.64 (0.52–0.79)
Analysis age-restricted cohort (>40 years) Other antidiabetic drug-exposed
group
553,942 515 1
GTZ-exposed group 262,113 175 0.73 (0.60–0.87)
Analysis cohort restricted to nonsmokers Other antidiabetic drug-exposed
group
197,324 184 1
GTZ-exposed group 86,699 52 0.69 (0.44–1.09)
Analysis cohort restricted to users of oral antidiabetic
agents
Other antidiabetic drug-exposed
group
460,917 426 1
GTZ-exposed group 261,746 173 0.78 (0.64–0.95)
* Adjusted for matched variables (age, gender, practice, and treatment stage) by conditional Poisson regression analysis.
** The rate of PD for current users of GTZ was originally divided into exposed <6 months, 6–12 months, and 1–2 years, but these cells were combined to
avoid small cells that could compromise anonymity. The crude rates in these three periods were all similar at between 4.36 and 4.94, so there was no
suggestion of important variation in that time period.
doi:10.1371/journal.pmed.1001854.t002
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investigating pioglitazone as a therapy to slow disease progression in early-stage PD in 216 par-
ticipants (Clinicaltrials.gov registration: NCT01280123), but this trial is not designed to assess
an effect on disease incidence. Our study provides unique evidence to support further investi-
gation of GTZ use in PD.
Evidence was found of an association between the use of both pioglitazone and rosiglitazone
and the onset of PD. Rosiglitazone was introduced to the market in 1999 but was eventually
suspended because of cardiovascular safety concerns [20]. However, in late 2013 the FDA
removed the prescribing and dispensing restrictions for rosiglitazone medicines that were put
into place in 2010 [21]. Whilst pioglitazone use has waned because of concerns over the risk of
bladder cancer, recent studies show that the association may be partly mediated by proteinuria
testing [22,23].
Stratifying by year of GTZ initiation did not change the main results, as strong associations
were found for relatively short follow-up periods of use.
Regarding the mechanisms of neuroprotection, glitazones have been shown to reduce the
expression of matrix metalloproteinases (MMP 3 and 9) by traumatised neurons, which are
known microglial activators as well as a direct anti-inflammatory on microglia [5]. GTZ drugs
have been shown to have a number of other neuroprotective properties in addition to their
anti-inflammatory effects. GTZ treatment, through its ability to up-regulate PGC-1alpha
expression, has been shown to increase brain mitochondrial biogenesis and the expression of
antioxidant enzymes and antiapoptotic factors [5,24–27]. Underexpression of peroxisome pro-
liferator-activated receptor-gamma coactivator (PGC)-1α has been identified as a potential
link for manifestations of defects in mitochondrial biogenesis and energetics [28]. Selective loss
of dopamine neurons in the substantia nigra can be reversed by PGC-1α expression in both in
vitro and in vivo models [28,29]. This could be potentially important since mitochondrial
deficits and oxidative stress have also been implicated in the pathogenesis of PD. Additional
peripheral mechanisms of neuroprotection may be through adiponectin, or adipocyte comple-
ment-related protein 30 (acrp30), which is elevated following the administration of PPAR
agonists and has anti-inflammatory properties in its own right [5]. Short-term treatment with
GTZ drugs in animal models produced dramatic neuroprotection, larger than what is often
observed by many neuroprotective compounds. Hence, even short-term treatment with GTZ
drugs in the presymptomatic phase of PD, when the nigrostriatal system will be fairly intact,
Table 3. IRR of PD adjusted for potential confounders.
Main Analysis* Adjusted for: Adjusted IRR** (95% CI)
Year at index date 0.71 (0.58–0.88)
Smoking 0.71 (0.59–0.86)
Use of alcohol 0.73 (0.60–0.89)
BMI 0.72 (0.59–0.87)
Head injury 0.72 (0.58–0.88)
Duration of diabetes 0.72 (0.59–0.87)
HbA1c levels at baseline 0.76 (0.63–0.92)
Use of CCB 0.73 (0.61–0.88)
Use of HRT 0.72 (0.60–0.87)
All variables 0.75 (0.59–0.94)
* Main analysis: IRR for the association between GTZ use and incident PD using conditional Poisson
regression to control for gender, age, practice, and treatment stage
doi:10.1371/journal.pmed.1001854.t003
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may be able to break the cycle of neurodegeneration by inhibiting the neuroinflammation pro-
cess and preventing or slowing disease onset [19].
Strengths and Limitations
Our cohort included a large study population of>160,000 diabetes patients from a health care
database with representative population coverage, in a setting with near-universal access to
medical care across the demographic and socioeconomic spectrum. As the electronic primary
care record is used to generate patient prescriptions, medication data are complete and accu-
rate. Repeat prescriptions are triggered by the patient; thus, our measures of drug use likely
reflect actual use. Misclassification of exposure periods could have occurred if patients were
not adhering completely to prescribed medicines, but diabetes is a serious condition for which
patients are likely to be motivated to take their medication, and any such misclassification is
likely to have been nondifferential with respect to PD status. Similarly, confounders such as
smoking status and alcohol use will be subject to some imprecision, but this is unlikely to be
differential according to GTZ user status.
Diagnoses of PD in CPRD have a positive predictive value of 81% (primary definition) to
90% (secondary definition) [13,30]. The results of a secondary analysis with a more stringent
definition of PD (clinical diagnosis plus at least two prescriptions for an anti-PD drug) gave
similar results (0.82 versus 0.72 in the primary analysis). Given the overall low prevalence of
PD, it is unlikely that a substantial number of patients were missed. As we did not take into
account any future treatment breaks or changes, we may have misclassified the exposure status
of individuals in our primary analysis. However, in a secondary analysis we allowed for treat-
ment changes and breaks (current versus past exposure to GTZ drugs) and found a strong
association with current use. Moreover, in a post hoc analysis, we compared current GTZ expo-
sure with current exposure to other treatments for diabetes, allowing for treatment breaks in
both groups: the strong association with current GTZ exposure remained (IRR 0.56, 95% CI
0.43–0.72). Any misclassification in our primary analysis is likely to have been nondifferential
and could have caused bias towards the null, or a potential underestimation of the protective
association.
The onset of PD in the context of the current study refers to the first recorded clinical diag-
nosis of PD in the CPRD. Patients are likely to have experienced symptoms before the date of
their clinical diagnosis. We compared the age of onset of PD between GTZ users and nonusers
but found no difference in average age, suggesting that GTZ drug do not simply delay the
appreciation of symptoms. A key clinical consideration is whether GTZ can slow PD progres-
sion after onset. Unfortunately, we cannot address this question with these data, as objective
markers of PD progression do not exist and measures of symptom progression are subjective
and poorly captured in the primary care record. Furthermore, increases in dosage of anti-PD
medication or the addition of added anti-PD therapies, e.g., catechol-O-methyltransferase
(COMT) inhibitors (used in patients with motor fluctuations), are not reliable markers of dis-
ease progression. When we attempted to compare the time to first PD treatment after the clini-
cal PD diagnosis, we found that a large number of GTZ users stopped their GTZ before PD
diagnosis. GTZ drugs, like all medications, have known side effects, and we are not making any
recommendations about their use in treating PD, since the balance of any potential benefits
and risks is entirely unknown at this stage.
Whilst we tried to select comparator groups that were as similar as possible to the GTZ
users, we cannot rule out unknown or unmeasured differences between the groups. The main
reason for nonmatches was the lack of similar patients per treatment stage, and this is a match-
ing criterion that cannot be weakened in a meaningful way. GTZ drugs are most often
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prescribed as a second-line treatment to patients who have responded less successfully to other
treatments for diabetes. We matched these patients to other users of second-line treatment at
the date of receipt of the add-on treatment. We controlled for the date of onset of diabetes and
HbA1c levels in a fully adjusted analysis. As the results were very similar to the results of the
primary analysis, we do not believe that GTZ patients in this study had a different underlying
risk of developing PD compared with users of other antidiabetic drugs. Adjusting for other
known predictors of PD (most notably smoking) did not appreciably change the estimated
association with GTZ use. As none of the potential risk factors were strongly associated with
the decision to prescribe a GTZ, only the matching variables were retained in the final model.
The study was conducted entirely within a patient population with diabetes, which may
affect the generalisability of our results. However, adjusting for duration of diabetes did not
have an effect on the results of the main analysis (IRR 0.72, 95% CI 0.59–0.87), and we believe
that it is unlikely that any pharmacological effect of GTZ drugs relevant to PD is limited to peo-
ple with diabetes only.
Conclusion
We found strong evidence for a protective association between GTZ exposure and the IR of
clinical presentation with PD in humans, consistent with previous evidence from animal and
in vitro studies. Our findings indicate that interventions based on the same mechanisms as
PPARγ agonist activity may be fruitful targets for future research in PD.
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Editors' Summary
Background
Parkinson’s disease (PD) is a common, progressive neurological disease. The condition is
caused by the gradual loss of nerve cells that normally produce dopamine, a neurotrans-
mitter that regulates the body’s movements. PD does not usually begin to develop until
people are around 60 years old, although it can sometimes affect younger people. Its symp-
toms, which develop slowly, include tremor (trembling of the hands, legs, arm, jaw, and
face), slow movement, and rigidity (muscle stiffness). As these symptoms worsen, affected
individuals may have trouble walking, speaking, swallowing, and sleeping, and they may
become depressed. No one has found a way to halt the loss of dopamine-producing nerve
cells yet, but medications that replace or mimic the lost dopamine can reduce the severity
of these symptoms. PD does not directly kill people, but it puts a great strain on the body
that can make affected individuals vulnerable to life-threatening infections. Nevertheless,
these days, many people with PD have a normal or near-normal life expectancy.
WhyWas This Study Done?
Recent experiments suggest that drugs that bind to the peroxisome proliferation-activated
receptor gamma (PPARγ agonist medications) may be neuroprotective (prevent nerve cell
loss) in animal models of PD. PPARγ regulates how the body uses fats and sugars, and
PPARγ agonist medications such as rosiglitazone and pioglitazone (glitazone [GTZ]
drugs) are used to treat people with diabetes, a condition characterized by high levels of
sugar in the blood. It is not known, however, whether GTZ drugs provide protection
against PD in people. In this retrospective cohort study, the researchers investigate
whether individuals with diabetes exposed to GTZ drugs have a lower incidence of PD
than individuals using other antidiabetic drugs. A retrospective cohort study uses data
already collected on a group (cohort) of people to look for associations between specific
characteristics such as use of a drug and outcomes.
What Did the Researchers Do and Find?
The researchers identified 44,597 patients with diabetes who were newly exposed to GTZ
drugs in the UK Clinical Practice Research Datalink, a database that contains primary care
data on more than 13 million individuals. They matched each patient with up to five users
of other antidiabetic drugs (120,373 controls) who were similar in terms of age, sex, atten-
dance at the same primary care practice, and diabetes treatment stage; people with diabetes
usually initially take a single drug but often switch to a different drug or to a combination
of drugs as their disease progresses. Finally, the researchers followed up the entire cohort
from January 1999 (when glitazones were introduced to treat diabetes) until diagnosis of
PD, the end of inclusion in the database, or the end of the study (August 2013). During fol-
low up, 175 glitazone users and 517 non-glitazone users were diagnosed with PD. The inci-
dence rates of PD among glitazone-using individuals and among users of other
antidiabetic treatments were 6.4 per 10,000 patient years and 8.8 per 10,000 patient years,
respectively (an incidence rate ratio [IRR] of 0.72; an IRR compares the rate of occurrence
of new cases of a disease in two groups of people). Adjustment for potential confounding
variables (characteristics that might affect an individual’s likelihood of developing PD)
Glitazones and Parkinson's Disease
PLOSMedicine | DOI:10.1371/journal.pmed.1001854 July 21, 2015 15 / 16
such as smoking and head injury did not alter the IRR. Notably, the risk of PD was reduced
among current users of GTZ drugs but not among past users.
What Do These Findings Mean?
These findings indicate that, among people with diabetes, current (but not past) GTZ use
is associated with a 28% lower rate of clinical presentation of PD compared to the use of
other antidiabetic drugs. Because the study only included patients with diabetes who did
not have a PD diagnosis when they started GTZ treatment, these findings cannot establish
whether GTZ use is associated with prevention of PD or with slower progression of the
disease. Moreover, the accuracy of these findings may be affected by misdiagnosis of PD
and misclassification of exposure periods to various antidiabetic drugs in the database and
by residual confounding. Finally, these findings may not be applicable to people without
diabetes. Importantly, the researchers do not recommend that GTZ drugs (which have
been associated with some serious side effects) be used as a treatment for PD. Rather, they
suggest that the pathways in which PPARγ is involved might contain potential drug targets
for PD and should be investigated in future research.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001854.
• The United States National Institute of Neurological Disorders and Stroke provides
detailed information about PD (in English and Spanish), including links to US organiza-
tions that help people with PD
• The UK National Health Service Choices website provides information on all aspects of
PD (including personal stories)
• The UK not-for-profit organization Parkinson'sUK and the US not-for-profit organiza-
tion National Parkinson Foundation also provide detailed information about PD and
personal stories
• The UK not-for-profit organization Healthtalk.Org provides stories about all aspects of
living with PD
• MedlinePlus has links to further resources about PD and information about
rosiglitazone and pioglitazone (in English and Spanish)
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